Versuchen Sie es noch einmal mit einem anderen Suchbegriff
Symbol | Börsenplatz | Währung | ||
---|---|---|---|---|
AMGN | NASDAQ | USD | Echtzeit | |
AMGN | BIVA | MXN | Verzögert | |
AMGN | Mexiko | MXN | Verzögert | |
AAMGN | Mailand | EUR | Echtzeit | |
AMGN | TradeGate | EUR | Verzögert | |
AMGN | Frankfurt | EUR | Verzögert | |
AMGN | Xetra | EUR | Verzögert | |
AMGN | Buenos Aires | ARS | Verzögert | |
AMGN34 | B3 | BRL | Verzögert | |
4332 | Hongkong | HKD | Verzögert | |
AMGN | Wien | EUR | Echtzeit |
AMGEN INC. ist ein Biotechnologie-Unternehmen. Das Unternehmen erforscht, entwickelt, produziert und liefert verschiedene menschliche Therapeutika. Das Geschäftsfeld des Unternehmens sind menschliche Therapeutika. Das vermarktete Sortiment an Produkten umfasst Neulasta (Pegfilgrastim); Erythropoese-stimulierende Wirkstoffe (ESA), wie z. B. Aranesp (Darbepoetin Alfa) und EPOGEN (Epoetin Alfa); Sensipar/Mimpara (Cinacalcet); XGEVA (Denosumab); Prolia (Denosumab); DAUER (Filgrastim) und andere Produkte, wie z. B. Vectibix (Panitumumab), Nplate (Romiplostim) und Corlanor (Ivabradin). Das Unternehmen konzentriert sich auf die Forschung und Entwicklung von menschlichen Therapeutika zur Behandlung von schweren Krankheiten in den Bereichen der Onkologie/Hämatologie, kardiovaskulären Erkrankungen, Entzündungen, Knochengesundheit, Nephrologie und Neurologie. Seine Produkte in Phase-III-Programmen umfassen Aranesp für myelodysplastische Syndrome; ENBREL für Psoriasis-Arthritis und rheumatoider Arthritisremission; IMLYGIC für metastasierende Melanome und Therapiebeginn für Multiples Myelom.
Name | Alter | Seit | Titel |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Robert A. Eckert | 69 | 2012 | Lead Independent Director |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
Ronald M. Evans | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Thomas Quertermous | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Elliott Sigal | - | - | Co-Chair of the Scientific Advisory Board |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Brian J. Druker | 68 | 2018 | Independent Director |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
Peter Libby | 76 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Wanda M. Austin | 69 | 2017 | Independent Director |
Amy E. Miles | 56 | 2020 | Independent Director |
S. Omar Ishrak | 67 | 2021 | Independent Director |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Ronald D. Sugar | 74 | 2010 | Independent Director |
R. Sanders Williams | 74 | 2014 | Independent Director |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Charles M. Holley | 66 | 2017 | Independent Director |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Michael V. Drake | 72 | 2022 | Independent Director |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Frank P. McCormick | 73 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
George Georgiou | 64 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Elizabeth McNally | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Drew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Antoni Ribas | - | - | Member of Scientific Advisory Board of Oncology |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Sind Sie sicher, dass Sie %USER_NAME% sperren möchten?
Dadurch werden Sie und %USER_NAME% nicht mehr in der Lage sein, Beiträge des jeweils anderen auf Investing.com zu sehen.
%USER_NAME% wurde erfolgreich zu Ihrer Sperrliste hinzugefügt.
Da Sie diese Person entsperrt haben, müssen Sie 48 Stunden warten, bevor Sie sie wieder sperren können.
Sagen Sie uns Ihre Meinung zu diesem Kommentar
Vielen Dank!
Ihre Meldung wurde zur Überprüfung an unsere Moderatoren geschickt